Visit-to-Visit variability of blood pressure and renal function decline in patients with diabetic chronic kidney disease

Journal of Clinical Hypertension

Volumn 16, Issue 5, 2014, Pages 362-366

  Yokota, Kei ^a,b,c   Fukuda, Masamichi ^b   Matsui, Yoshio ^b   Kario, Kazuomi ^a   Kimura, Kenjiro ^c  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Iwakuni Medical Center   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE VARIABILITY; BLOOD PRESSURE VISIT TO VISIT VARIABILITY; CARDIOVASCULAR PARAMETERS; CHRONIC KIDNEY DISEASE; CORRELATIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AMBULATORY CARE; CHRONIC DISEASE; COMPLICATION; DIABETIC NEPHROPATHY; DISEASE COURSE; FOLLOW UP; HYPERTENSION; KIDNEY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS;

AGED; BLOOD PRESSURE; CHRONIC DISEASE; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; MALE; OFFICE VISITS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84900398935     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12293     Document Type: Article

References (40)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038-2047.
2. Gilbertson DT, Liu J, Xue JL, et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol. 2005;16:3736-3741.
3. Stengel B, Billon S, Van Dijk PC, et al. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant. 2003;18:1824-1833.
4. Kerr M, Bray B, Medcalf J, et al. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant. 2012;27(Suppl 3):iii73-iii80.
5. Centers for Disease Control and Prevention (CDC). Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes - United States and Puerto Rico, 1996-2007. MMWR Morb Mortal Wkly Rep. 2010;59:1361.
6. Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand J Clin Lab Invest. 1976;36:383-388.
7. Parving H-H, Smidt UM, Friisberg B, et al. A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia. 1981;20:457-461.
8. Viberti GC, Bilous RW, Mackintosh D, et al. Monitoring glomerular function in diabetic nephropathy. Am J Med. 1983;74:256-264.
9. Hovind P, Rossing P, Tarnow L, et al. Progression of diabetic nephropathy. Kidney Int. 2001;59:702-709.
10. Hata Y, Kimura Y, Muratani H, et al. Office blood pressure variability as a predictor of brain infarction in elderly hypertensive patients. Hypertens Res. 2000;23:553-560.
11. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895-905.
12. Hata Y, Muratani H, Kimura Y, et al. Office blood pressure variability as a predictor of acute myocardial infarction in elderly patients receiving antihypertensive therapy. J Hum Hypertens. 2002;16:141-146.
13. Muntner P, Shimbo D, Tonelli M, et al. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension. 2011;57:160-166.
14. Mallamaci F, Minutolo R, Leonardis D, et al. Long-term visit-to-visit office blood pressure variability increases the risk of adverse cardiovascular outcomes in patients with chronic kidney disease. Kidney Int. 2013;84:381-389.
15. McMullan CJ, Bakris GL, Phillips RA, Forman JP. Association of BP variability with mortality among African Americans with CKD. Clin J Am Soc Nephrol. 2013;8:731-738.
16. Yokota K, Fukuda M, Matsui Y, et al. Impact of visit-to-visit variability of blood pressure on deterioration of renal function in patients with non-diabetic chronic kidney disease. Hypertens Res. 2013;36:151-157.
17. Okada H, Fukui M, Tanaka M, et al. Visit-to-visit blood pressure variability is a novel risk factor for the development and progression of diabetic nephropathy in patients with type 2 diabetes. Diabetes Care. 2013;36:1908-1912.
18. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3:1-150.
19. Kidney Disease Outcomes Quality Initiative (KDOQI). KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49:S12-S154.
20. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1-S290.
21. Hollenberg NK, Raij L. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Arch Intern Med. 1993;153:2426-2435.
22. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
23. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
24. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
25. Rosman JB, ter Wee PM, Meijer S, et al. Prospective randomised trial of early dietary protein restriction in chronic renal failure. Lancet. 1984;2:1291-1296.
26. Nagai M, Hoshide S, Ishikawa J, et al. Visit-to-visit blood pressure variations: new independent determinants for carotid artery measures in the elderly at high risk of cardiovascular disease. J Am Soc Hypertens. 2011;5:184-192.
27. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-992.
28. de Goeij MC, Voormolen N, Halbesma N, et al. The PREPARE-1 Study Group. Association of blood pressure with decline in renal function and time until the start of renal replacement therapy in pre-dialysis patients: a cohort study. BMC Nephrol. 2011;12:38-47.
29. Rothwell PM, Howard SC, Dolan E, et al. ASCOT-BPLA and MRC Trial Investigators. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9:469-480.
30. Okada H, Fukui M, Tanaka M, et al. Visit-to-visit variability in systolic blood pressure is correlated with diabetic nephropathy and atherosclerosis in patients with type 2 diabetes. Atherosclerosis. 2012;220:155-159.
31. Østerby R. Early phases in the development of diabetic glomerulopathy. A quantitative electron microscopic study. Acta Med Scand. 1975;574:1-80.
32. Hayashi H, Karasawa R, Inn H, et al. An electron microscopic study of glomeruli in Japanese patients with non-insulin dependent diabetes mellitus. Kidney Int. 1992;41:749-757.
33. Mauer SM, Barbosa J, Vernier RL, et al. Development of diabetic vascular lesions in normal kidneys transplanted into patients with diabetes mellitus. N Engl J Med. 1976;295:916-920.
34. Pagtalunan ME, Miller PL, Jumping-Eagle S. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1996;99:342-348.
35. White KE, Bilous RW. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant. 2004;19:1437-1440.
36. Dalla VM, Masiero A, Roiter AM, et al. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes Diabetes. 2003;52:1031-1035.
37. Najafian B, Crosson JT, Kim Y, et al. Glomerulotubular junction abnormalities are associated with proteinuria in type 1 diabetes. J Am Soc Nephrol. 2006;17:S53-S60.
38. Ritz E, Haxsen V. Diabetic nephropathy and anaemia. Eur J Clin Invest. 2005;35:66-74.
39. Muntner P, Levitan EB, Joyce C, et al. Association between antihypertensive medication adherence and visit-to-visit variability of blood pressure. J Clin Hypertens (Greenwich). 2013;15:112-117.
40. Muntner P, Joyce C, Levitan EB, et al. Reproducibility of visit-to-visit variability of blood pressure measured as part of routine clinical care. J Hypertens. 2011;29:2332-2338.